Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2013

Melior Licenses Insulin Sensitizer to Bukwang

  • Melior Pharmaceuticals inked a licensing agreement with South Korea-based Bukwang Pharmaceutical to develop, manufacture, and commercialize MLR-1023, an insulin sensitizer for the treatment of type 2 diabetes.

    As part of the agreement, Bukwang will receive an exclusive license to MLR-1023 and related compounds for specified countries in the Asia-Pacific region excluding Japan and support preclinical and clinical studies to be conducted in the U.S. and South Korea aimed at bringing MLR-1023 through Phase IIb proof-of-concept trials. The company also acquires an option to access Melior technology related to the underlying mechanism of action of MLR-1023. Melior will receive an upfront cash payment as well as payments upon achievement of certain development and regulatory milestones.

    According to Melior, MLR-1023 improves glycemic control by directly and selectively activating the Lyn tyrosine kinase enzyme, which has been shown to modulate insulin-signaling pathways independently of PPAR mechanisms. Preclinical studies show that MLR-1023 has the potential to lower blood glucose levels more effectively than existing therapies without the risk of hypoglycemia or weight gain, the company said.

    MLR-1023, formerly known as tolimidone, was previously in clinical development by Pfizer for an anti-ulcer indication. It was discontinued after Phase II due to a lack of efficacy in the anti-ulcer indication.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »